Taro Pharma (TARO) Posts Inline Q4 Breakeven Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Taro Provides Results for Year Ended March 31, 2015
May 26, 2015 6:44 PM EDTNet Sales Increases 14%, Operating Income and E.P.S. Up 23% and 39%, respectively
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and year ended March 31, 2015.
Quarter ended March 31, 2015 Highlights - compared to March 31, 2014
Net sales of $244.2 million, increased $57.0 million, or 30.5%, on flat volumes Gross profit, as a percentage of net sales, was 81.8%, compared to 75.5% an increase of $58.3 million or 41.2% Research and development expenses increased $10.7 million to $23.9 million... More